Back to results
US 2022/0177427 A1Published application
Tryptamine Prodrugs
AssigneeField Trip Psychedelic Inc.
InventorNathan Bryson
Life of this patent
Estimating the term…
Abstract
The present invention provides a tryptamine prodrug compound. A compound represented by the formula (I) where each symbol is as described in the specification, or a salt or zwitterion thereof, is converted to an active which has 5HT2A receptor agonist activity, and is useful as an agent for the treatment of depression.
Claims1
A compound of Formula (I) (II), (III) or (IV) or a pharmaceutically acceptable salt or zwitterion thereof:
- wherein:
- (1) R1, R2, and R6 are each independently selected from hydrogen, linear or branched alkyl, or arylalkyl;
- (2) R4 is
- a. —X—CO2H, where X is a linear, cyclic or branched, saturated or unsaturated carbon chain, optionally substituted with —OH or —CO2H;
- or an aromatic ring, optionally substituted with alkyl or CO2H;
- or
- b.
- wherein R9 is X—CO2H, where X is as defined in (2)(a) above and R10 is hydrogen, linear or branched alkyl or arylalkyl, optionally substituted by —OH or —CO2H;
- (3) R5 is hydrogen, linear or branched alkyl, arylalkyl, or O—R5′, where R5′ is hydrogen, linear or branched alkyl;
- and
- (4) R7 and R8:
- a. are each independently selected from hydrogen, linear or branched alkyl, or arylalkyl, or
- b. together form a non-aromatic N-containing heterocycle, optionally substituted with alkyl.
10 more elements
Dependencies are inferred from the claim text.